These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 22137628)

  • 1. [Organisation of combined follow-up by hospitals and private dermatologists].
    Le Maître M; Beylot-Barry M
    Ann Dermatol Venereol; 2011 Dec; 138(12):854-6. PubMed ID: 22137628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: review of the literature and results of a survey sent to 100 dermatologists.
    Katz HI
    J Am Acad Dermatol; 1997 Sep; 37(3 Pt 2):S62-8. PubMed ID: 9344188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developments in systemic immunomodulatory therapy for psoriasis.
    Berger EM; Gottlieb AB
    Curr Opin Pharmacol; 2007 Aug; 7(4):434-44. PubMed ID: 17627886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of psoriasis. Part 2. Systemic therapies.
    Lebwohl M; Ali S
    J Am Acad Dermatol; 2001 Nov; 45(5):649-61; quiz 662-4. PubMed ID: 11606913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exacerbation of paranoid schizophrenia in a psoriatic patient after treatment with cyclosporine A, but not with etanercept.
    Di Nuzzo S; Zanni M; De Panfilis G
    J Drugs Dermatol; 2007 Oct; 6(10):1046-7. PubMed ID: 17966184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine.
    Opmeer BC; Heydendael VM; De Borgie CA; Spuls PI; Bossuyt PM; Bos JD; De Rie MA
    Arch Dermatol; 2004 Jun; 140(6):685-90. PubMed ID: 15210458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current systemic therapies for psoriasis: where are we now?
    Yamauchi PS; Rizk D; Kormeili T; Patnaik R; Lowe NJ
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S66-77. PubMed ID: 12894129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cyclosporine].
    Paul C; Garat H
    Ann Dermatol Venereol; 2011 Dec; 138(12):836-8. PubMed ID: 22137622
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prescription and surveillance of treatment by a systemic agent or biotherapy in psoriasis].
    Boulinguez S
    Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):8-12. PubMed ID: 20510169
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclosporine: what clinicians need to know.
    Koo J; Lee J
    Dermatol Clin; 1995 Oct; 13(4):897-907. PubMed ID: 8785893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of ciclosporin in psoriasis: a clinical review.
    Ho VC
    Br J Dermatol; 2004 May; 150 Suppl 67():1-10. PubMed ID: 15115440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe psoriasis treated with a new macrolide: everolimus.
    Frigerio E; Colombo MD; Franchi C; Altomare A; Garutti C; Altomare GF
    Br J Dermatol; 2007 Feb; 156(2):372-4. PubMed ID: 17223881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic combination treatment for psoriasis: a review.
    Jensen P; Skov L; Zachariae C
    Acta Derm Venereol; 2010 Jul; 90(4):341-9. PubMed ID: 20574597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
    Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment policy for psoriasis and eczema: a survey among dermatologists in the Netherlands and Belgian Flanders.
    Roelofzen JH; Aben KK; Khawar AJ; Van de Kerkhof PC; Kiemeney LA; Van Der Valk PG
    Eur J Dermatol; 2007; 17(5):416-21. PubMed ID: 17673386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inpatient and outpatient follow-up of grade I malignant melanoma].
    Cordel N; Safa G; Balguerie X; De Preville P; Modeste A; Courville P; Boivin C; Pellerin A; Ziade J; Thiberville G; Laaengh-Michel N; Neveu C; Young P; Lauret P; Joly P
    Ann Dermatol Venereol; 2000; 127(6-7):579-83. PubMed ID: 10930854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation.
    Cordero-Coma M; Anzaar F; Sobrin L; Foster CS
    Ocul Immunol Inflamm; 2007; 15(2):99-104. PubMed ID: 17558834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Patient education. Information letter on treatment of psoriasis with oral cyclosporine].
    Groupe de recherche sur psoriasis de Société française de dermatologie, Mai 2011
    Ann Dermatol Venereol; 2011 Dec; 138(12):863-4. PubMed ID: 22137632
    [No Abstract]   [Full Text] [Related]  

  • 19. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment.
    Puig L
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1007-11. PubMed ID: 21492252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early and explosive development of nodular basal cell carcinoma and multiple keratoacanthomas in psoriasis patients treated with cyclosporine.
    Lain EL; Markus RF
    J Drugs Dermatol; 2004; 3(6):680-2. PubMed ID: 15624753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.